Rising Pharma recalls cetirizine hydrochloride tablets

Rising Pharma Holdings Inc voluntarily recalled four lots of cetirizine hydrochloride tablets USP 5 mg on July 18, 2026 due to possible cross-contamination with ranitidine.

The recall applies to 100-count bottles with NDC 16571-401-10, expiration date October 2028, and lot numbers GY825029, GY825030, GY825031, and GY825032.

Consumers with sensitivity to ranitidine may face serious health risks including anaphylaxis, though no adverse reactions have been reported yet.

The FDA advises affected consumers to seek medical advice and stop using the recalled medication.